SLC5A2 and chronic kidney disease: Sodium–glucose cotransporter-2 (SGLT2) inhibitors are widely used not only for patients with diabetes mellitus (DM) but also for patients with congestive heart failure (CHF) and chronic kidney disease (CKD) regardless of DM status.